| Ying Li,Qiaofang Li,Yanluqi He,Hongzhen Zhang. The prognostic significance of ALI, PLR, and Ki-67 expression in stage III–IV inoperable non-small cell lung cancer. Oncol Transl Med, 2021, 7: 7-14. |
| 河北省医学科学研究重点课题 |
| The prognostic significance of ALI, PLR, and Ki-67 expression in stage III–IV inoperable non-small cell lung cancer |
| Received:June 23, 2020 Revised:February 19, 2021 |
| DOI：10.1007/s10330-020-0441-1 |
| 中文关键词: 非小细胞肺癌；晚期肺癌炎症指数；Ki67预后 |
| 英文关键词: non-small cell lung cancer (NSCLC); advanced lung cancer inflammation index (ALI); expression of Ki-67; prognosis |
| 基金项目:河北省医学科学研究重点课题 |
| Author Name | Affiliation | E-mail | | Ying Li | 1.Graduate School of Hebei North University | 349546474@qq.com | | Qiaofang Li | 1.Graduate School of Hebei North University | | | Yanluqi He | 1.Graduate School of Hebei North University | | | Hongzhen Zhang* | 1.Graduate School of Hebei North University | hongzhenzhang456@sohu.com |
|
| Hits: 9564 |
| Download times: 12903 |
| 中文摘要: |
| 目的：探讨并比较治疗前肺癌晚期炎症指数、血小板与淋巴细胞比及Ki67表达对III-IV期不可手术的非小细胞肺癌预后的评估价值；
方法：采用回顾性分析我院98例治疗前III-IV期不可手术的非小细胞肺癌患者临床资料，以体重指数（BMI）×血清白蛋白(ALB)／中性粒细胞／淋巴细胞比值（NLR）计算晚期肺癌炎症指标。以血小板/淋巴细胞为血小板淋巴细胞比，采用卡方检验分析患者与临床特征的关系。采用Kaplan-Meier法计算患者总生存期，并用log-rank检验进行比较。采用单因素和多因素分析评估独立预后因素。采用Spearman相关分析ALI、PLR、Ki67的关系。
结果：98例患者中，In our study,ALI＜18的患者的生存时间明显低于ALI＞18的患者（P＜0.001），中位生存时间分别为10个月和25个月。PLR＜185的患者的生存期明显高于PLR＞185的患者（中位生存时间为27个月VS10个月，P＜0.001）。Ki67表达越高，患者生存时间越短（P＜0.005）。ALI和PLR联合检测结果提示高ALI同时伴有低PLR的患者生存时间显著长于低水平ALI值和伴有高水平PLR的患者（P＜0.001）。单因素分析结果显示，吸烟史、分化程度、KPS评分、Ki67表达、ALI值、PLR影响患者预后；多因素分析显示KPS评分、ALI值、Ki67表达是独立预后因素 |
| 英文摘要: |
| Objective The aim of the study was to investigate and compare the prognostic value of advanced
inflammatory index, platelet/lymphocyte ratio (PLR), and Ki-67 expression in stage III–IV inoperable nonsmall cell lung cancer (NSCLC) before treatment.
Methods The clinical data of 98 inoperable patients with stage III–IV NSCLC in our hospital (Fifth
Department of Oncology, Hebei General Hospital, Shijiazhuang, China) before treatment were
retrospectively analyzed, and advanced lung cancer inflammation index (ALI) was calculated using body
mass index (BMI) × serum albumin (ALB) ÷ neutrophil/lymphocyte ratio (NLR). he optimal cutoff values of
ALI and PLR for predicting prognosis is determined. Chi-square test was used to analyze the relationship
between patients and clinical characteristics. Kaplan-Meier method was used to calculate the total survival
of patients, and log-rank test was used for comparison. Independent prognostic factors were assessed by
univariate and multivariate analyses. Spearman correlation was used to analyze the relationship among
ALI, PLR, and Ki-67.
Results In our study of the 98 cases, the survival time of the patients with ALI < 18 was significantly lower
than that of patients with ALI > 18 (P < 0.001), with a median survival time of 10 months and 25 months,
respectively. The survival time of patients with a PLR < 185 was significantly higher than that of patients
with a PLR > 185 (median survival time was 27 months vs. 10 months, P < 0.001).The higher the Ki-67
expression, the shorter the survival time (P < 0.005).The combined ALI and PLR detection results indicated
that the survival time of patients with high ALI and low PLR was significantly longer than that of patients with
low ALI and high PLR (P < 0.001). Univariate analysis showed that smoking history, degree of differentiation,
KPS score, Ki-67 expression, ALI value, and PLR affected the prognosis of patients. Multivariate analysis
showed that KPS score, ALI value, and Ki-67 expression were independent prognostic factors.
Conclusion ALI, PLR, and Ki-67 expression are important predictors of stage III-IV inoperable NSCLC.
In terms of the prognostic value, ALI seems to have the best ability to predict patient survival. In addition,
the combined detection of ALI and PLR levels before treatment seems to be more helpful in improving our
prediction of patient prognosis. Moreover, it is expected to play a role in future clinical applications. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|